AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00764673 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3DKnee
Description: Subjects with knee osteoarthritis and willing to participate in the study
Study NCT01014468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Intravitreal injection)
Description: Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
Study NCT01014468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Intravitreal injection)
Description: Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
Study NCT00131404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo capsule once daily. 52 week treatment period.
Study NCT00637663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg QD
Study NCT00637663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study NCT01644604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2211 Renal Denervation System
Description: A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
Study NCT02741557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
Study NCT02741557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
Study NCT02104570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping with tension
Study NCT02104570 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio taping without tension
Study NCT02104570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fatigue protocol
Study NCT02104570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Study NCT02104570 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fatigue protocol
Study NCT00448305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 + paclitaxel
Description: EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
Study NCT00448305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Description: EndoTAG-1 44 mg/m² twice weekly
Study NCT00448305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m² weekly
Study NCT02741557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV FDC
Description: DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
Study NCT01973361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound debridement
Description: Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
Study NCT00159224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir simplification strategy
Description: Simplification
Study NCT01973361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best practice wound care
Description: Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
Study NCT00546884 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MI condition
Description: Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
Study NCT01758653 — intervention group
Intervention type: OTHER
Intervention: No study intervention
Description: There is no study-related intervention.
Study NCT00159224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir simplification strategy
Description: Simplification
Study NCT02540083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBT and FFDM
Description: Subjects underwent FFDM breast imaging followed by DBT breast imaging
Study NCT00261443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium or Valproate with placebo (PBO)
Description: Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily
Study NCT00261443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium or Valproate with Aripiprazole
Description: Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day
Study NCT04259957 — intervention group
Intervention type: DEVICE
Intervention: Immersive Virtual Reality
Description: Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
Study NCT01293240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
Study NCT00546884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GI
Description: The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
Study NCT01870336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined treatment of medial knee osteoarthritis
Study NCT00444054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet (approximately 20 grams per day)
Description: Very low carbohydrate diet for a duration of four weeks.
Study NCT02598388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
Study NCT02354404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ
Description: cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
Study NCT02354404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO
Description: 1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
Study NCT02354404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Study NCT01284452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 50 ml intravenous every 6 hours for 7 days
Study NCT01284452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 50 mg intravenous every 6 hours for 7 days
Study NCT04756115 — intervention group
Intervention type: PROCEDURE
Intervention: Vascular Surgery.
Description: Open Vascular, endovascular or hybrid procedures.
Study NCT02644915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
Study NCT02644915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%%NaCl solution
Description: 100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg
Study NCT04659369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB819
Description: for injection only
Study NCT04659369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: for injection only
Study NCT00329082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks
Study NCT00329082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5: Placebo QW IV for 12 weeks
Study NCT03443531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Huatan granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
Study NCT03443531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yifei Qinghua granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
Study NCT03443531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bufei Huatan granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
Study NCT03443531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Yifei Qinghua granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
Study NCT00369941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0518
Description: 400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
Study NCT00369941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: efavirenz
Description: 600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
Study NCT00369941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Truvada
Description: One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
Study NCT00369941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Truvada
Description: One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
Study NCT00369941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to MK-0518
Description: Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
Study NCT00369941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to efavirenz
Description: Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
Study NCT03706482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOOST cells
Description: Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
Study NCT04000282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442085
Description: Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
Study NCT01644383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: logotherapy
Description: Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
Study NCT01959061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 4mg, every 4 weeks,transhepatic arterial infusion
Study NCT01959061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100\~150mg, every 4 weeks, transhepatic arterial infusion
Study NCT01959061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipiodol
Description: 5-20ml, every 4 weeks, hepatic artery embolization
Study NCT00061932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01640262 — intervention group
Intervention type: OTHER
Intervention: Multiparametric magnetic resonance imaging (mMRI)
Description: A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
Study NCT03776461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
Study NCT03776461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
Study NCT02295605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water-based exercises
Description: water-based exercise strengthening protocol for lower limb muscles
Study NCT02295605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: land-based exercises
Description: land-based exercise strengthening protocol for lower limb muscles
Study NCT01805037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV
Study NCT01805037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01805037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00288327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle behavior change program
Description: Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
Study NCT00288327 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pamphlets
Description: Nutritional and physical activity pamphlets from American Heart Association
Study NCT03517566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily from baseline until week 16
Study NCT03517566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 3mg
Description: ZPL389 3 mg oral powder; once daily from baseline to week 16
Study NCT03517566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 10mg
Description: ZPL389 10 mg oral powder; once daily from baseline to week 16
Study NCT03517566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 30mg
Description: ZPL389 30 mg oral powder; once daily from baseline to week 16
Study NCT03517566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 50mg
Description: ZPL389 50 mg oral powder; once daily from baseline to week 16
Study NCT03883932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatherhood Focused FVEP (F3)
Description: F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
Study NCT03883932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Violence Education Program (FVEP)
Description: FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
Study NCT02488681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micra Pacemaker Implant
Study NCT02973308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observer
Description: Observer A and observer B
Study NCT00003824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Study NCT00003824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 mg oral bid for 3 days starting the night before resection
Study NCT00697242 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses
Study NCT00697242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
Description: Intramuscular injection, 3 doses
Study NCT02978339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
Study NCT01721213 — intervention group
Intervention type: DRUG
Intervention: Trobalt™
Description: Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
Study NCT03045497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV
Study NCT03045497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo contrast-enhanced ultrasound imaging
Study NCT03045497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced Magnetic Resonance Imaging
Study NCT04414150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1802
Description: This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
Study NCT01087216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group Laser = Arm A
Description: Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
Study NCT01087216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bras B : The group control
Description: patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
Study NCT00844558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
Study NCT00844558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: There is no intervention associated with this arm of the study
Study NCT02307162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: Phosphodiesterase 3 and 4 Inhibitor
Study NCT02307162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dummy solution
Study NCT04505579 — intervention group
Intervention type: DEVICE
Intervention: Anterior Vertebral Body Tethering
Description: Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
Study NCT04038762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cuff deflation-inflation -deflation method
Description: Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
Study NCT04038762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cuff deflation-inflation -deflation method
Description: Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps